spacer
The Healthcare Sales & Marketing Network celebrates 23 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  rivastigmine 

 HSMN NewsFeed - 30 Apr 2020
Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 14 Jan 2019
Amneal Announces Approval of Rivastigmine Transdermal System
Biopharmaceuticals Drug Delivery Generics FDA
 HSMN NewsFeed - 9 Jul 2018
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon(R) Patch
Biopharmaceuticals Neurology Generics Product Launch
 HSMN NewsFeed - 28 May 2018
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 1 Dec 2016
Luye Pharma Announces the Completion of Acquisition of Acino's Transdermal Drug Delivery Systems Business
Biopharmaceuticals Drug Delivery Acquisitions
 HSMN NewsFeed - 4 Sep 2012
Higher dose of Novartis drug Exelon(R) Patch approved by FDA for patients with mild to moderate Alzheimer's disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 Aug 2010
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jul 2008
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Jan 2008
Dr. Reddy's Announces Settlement of Exelon(R) (rivastigmine tartrate) ANDA Litigation With Novartis
Biopharmaceuticals Generics Neurology Litigation
 HSMN NewsFeed - 6 Dec 2007
Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 19 Jul 2006
Exelon(R) Patch, the first transdermal therapy for Alzheimer's disease, may provide a promising new approach to treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Jun 2006
The U.S. Food and Drug Administration Approves Exelon(R) (rivastigmine tartrate) as the First Medication Indicated to Treat Parkinson's Disease Dementia
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 17 May 2006
FDA Advisory Committee Recommends Approval of Exelon(R) (rivastigmine tartrate) in the Treatment of Dementia Associated with Parkinson's Disease
Biopharmaceuticals Neurology FDA
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
rivastigmine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.